Market Place
Sourcing Support
PharmAla Teams Up With Veridion Group For Exclusive Distribution
25 Sep 2025 //
GLOBENEWSWIRE
PharmAla Ships LaNeo™ MDMA to Yale, Updates Investors
03 Jun 2025 //
GLOBENEWSWIRE
PharmAla Announces Private Placement
13 Dec 2024 //
GLOBENEWSWIRE
PharmAla Launches MDMA Therapy Prescriber`s Portal
03 May 2024 //
GLOBENEWSWIRE
PharmAla Closes Private Placement and Concurrent Debt Settlement
19 Apr 2024 //
GLOBENEWSWIRE
PharmAla Announces Private Placement and Concurrent Debt Settlement
10 Apr 2024 //
GLOBENEWSWIRE
Cortexa Commences Manufacturing GMP LaNeo„ MDMA in Australia
05 Apr 2024 //
GLOBENEWSWIRE
Patent Allowance Granted for ALA-002 Composition by US Patent
27 Mar 2024 //
GLOBENEWSWIRE
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20 Mar 2024 //
GLOBENEWSWIRE
Cortexa Leads the World in First Supply of Psilocybin Under TGA`s Authorized
18 Mar 2024 //
GLOBENEWSWIRE
Cortexa Leads the World in First Supply of Psilocybin Under the TGA
18 Mar 2024 //
GLOBENEWSWIRE
PharmAla Announces Voting Results of Annual General and Special Meeting
08 Mar 2024 //
GLOBENEWSWIRE
PharmAla named an Intellectual Property Ontario Client
22 Feb 2024 //
GLOBENEWSWIRE
PharmAla Data to be Published in ACS Chemical Neuroscience
20 Feb 2024 //
GLOBENEWSWIRE
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09 Feb 2024 //
GLOBENEWSWIRE
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31 Jan 2024 //
GLOBENEWSWIRE
PharmAla granted Controlled Drugs & Substances Dealers License by Health Canada
25 Jan 2024 //
GLOBENEWSWIRE
PharmAla receives new MDXXF ticker from FINRA for OTCQB Listing
24 Jan 2024 //
GLOBENEWSWIRE
PharmAla Files Audited Financials for Year Ending August 31, 2023
29 Dec 2023 //
GLOBENEWSWIRE
PharmAla and Filament Announce Release of Second Batch of GMP MDMA Capsules
15 Nov 2023 //
GLOBENEWSWIRE
PharmAla Partners with Clariti Strategic Advisors„¢
08 Nov 2023 //
GLOBENEWSWIRE
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07 Nov 2023 //
GLOBENEWSWIRE
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
25 Sep 2023 //
GLOBENEWSWIRE
PharmAla Begins Trading on OTCQB
06 Sep 2023 //
GLOBENEWSWIRE
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
10 Aug 2023 //
GLOBENEWSWIRE
PharmAla Received Guidance on ALA-002 from MHRA
20 Jul 2023 //
GLOBENEWSWIRE
Transactions in connection with share buy-back program
04 Jul 2023 //
GLOBENEWSWIRE
PharmAla Awarded Research Grant by Ontario Centre for Innovation
09 Jun 2023 //
GLOBENEWSWIRE
PharmAla & Shaman Granted First Ever Special Access Authorization for MDMA
16 May 2023 //
GLOBENEWSWIRE
Mindset and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin
06 Mar 2023 //
GLOBENEWSWIRE
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
06 Feb 2023 //
GLOBENEWSWIRE
Australia Allows Prescription of MDMA and Psilocybin in Regulatory Change
03 Feb 2023 //
GLOBENEWSWIRE
PharmAla Biotech granted an Export Permit for 300 grams of LaNeo MDMA
24 Jan 2023 //
GLOBENEWSWIRE
Canadian and US developers to trial psychedelic medicines in UK
13 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
16 Nov 2022 //
GLOBENEWSWIRE
